What is TG Therapeutics's market cap?

TG Therapeutics (TGTX) has a market capitalization of $8.5B and trades on NASDAQ.

What is TG Therapeutics's revenue and profitability?

TG Therapeutics generated $700.3M in trailing twelve-month revenue with net income of $461.9M, representing a net margin of 66.0%. Gross margin stands at 83.1%, with free cash flow of -$95.6M. These figures are based on the Q1 2026 filing.

Who are TG Therapeutics's competitors?

TG Therapeutics's key competitors include Biogen Inc., Vor Biopharma Inc. Common Stock, Soligenix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does TG Therapeutics partner with?

TG Therapeutics's notable partners include Neuraxpharm Pharmaceuticals, S.L., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, and others.

What subsidiaries does TG Therapeutics have?

TG Therapeutics's subsidiaries include TG Cell Therapy, Inc..

Where is TG Therapeutics headquartered?

TG Therapeutics is headquartered in United States of America and employs approximately 264 people. It has been publicly traded since 1995.

TG Therapeutics

TGTX

TG Therapeutics is a fully integrated, commercial-stage biotechnology company dedicated to acquiring, developing, and commercializing novel treatments for B-cell mediated diseases.

Market cap

$8.53B+48.2%

Revenue$700.3M+81.3%

Net income$461.9M+1,080%

Free cash flow-$95.6M-66.2%

EPS (diluted)$2.87+1,096%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$204.9MBeat by $4.6M EPS$0.17Miss by $0.06

Read the full report

Next report

Aug 3, 2026 (In 5 days)

Revenue estimate$229.8M

EPS estimate$0.31

Financials

Q1 2026

Income statement

See full

Revenue$204.9M+69.6%

Gross profit$171.4M+62.8%

Operating income$34.8M+304%

Net income$19.8M+291%

EPS (diluted)$0.12+300%

Balance sheet

See full

Cash & equivalents$442.2M+235%

Total debt$753.6M+197%

Total equity$583.1M+146%

Total assets$1.5B+133%

Cash flow

See full

Operating cash flow-$17.9M+37.7%

CapEx$51.0K+104%

Free cash flow-$17.9M+37.6%

Valuation & ratios

Valuation

See full

Market cap$8.53B+48.2%

Enterprise value$8.85B+51.5%

P/E18.5×-76.0×

P/S12.2×-0.4×

Profitability

See full

Gross margin83.1%-4.4pp

Operating margin21.3%+5.9pp

Net margin66%+55.8pp

Returns & leverage

See full

Return on equity112.6%+92.9pp

Debt / equity1.3×+0.2×

Current ratio5.8×+1.8×

Competitors

By market cap

AbbVie$453.91B+36.3%

Biogen$29.5B+56.0%

TG Therapeutics$8.5B+49.4%

Ultragenyx Pharmaceutical$2.6B+1.5%

Vor Biopharma$1.1B+248%

Rigel Pharmaceuticals$691.8M+93.6%

Shattuck Labs, Inc.$672.4M+1,610%

Soligenix, Inc.$5.4M+28.4%

By revenue growth

TG Therapeutics+81.3%

Rigel Pharmaceuticals+47.6%

Ultragenyx Pharmaceutical+13.5%

AbbVie+9.5%

Biogen+0.3%

Shattuck Labs, Inc.-78.3%

By net margin

Rigel Pharmaceuticals121.51%+103pp

TG Therapeutics65.95%+55.8pp

Biogen8.81%-6.5pp

AbbVie5.79%-1.5pp

Ultragenyx Pharmaceutical-90.92%+2.2pp

Shattuck Labs, Inc.-4,987.4%-3,454pp

Profile

TG Therapeutics is a fully integrated, commercial-stage biotechnology company dedicated to acquiring, developing, and commercializing novel treatments for B-cell mediated diseases. The company's primary focus is on autoimmune disorders, particularly multiple sclerosis, where it leverages a clinical development platform to identify and advance potentially best-in-class compounds.

Competitive position

A commercial-stage player in the MS market with a differentiated anti-CD20 monoclonal antibody offering shorter infusion times than some established competitors.

GeographiesUnited States, European Union, Germany

Customer segmentsPatients, Healthcare Providers, Pharmaceutical Distributors

Business modelDirect-to-market, Licensing and Royalties, Research and Development

SuppliersContract manufacturing organizations, Academic centers of excellence, Raw material suppliers, Genome editing technology providers

CustomersSpecialty pharmacies, Hospitals, Infusion centers, International commercialization partners

CountryUnited States of America

Listed1995

Employees264.0

CEOMichael S. Weiss

SectorHealthcare

IndustryBiotechnology

Websitetgtherapeutics.com

FilingsSEC EDGAR

Ask your AI about TG Therapeutics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TG Therapeutics's market cap?: TG Therapeutics (TGTX) has a market capitalization of $8.5B and trades on NASDAQ.
What is TG Therapeutics's revenue and profitability?: TG Therapeutics generated $700.3M in trailing twelve-month revenue with net income of $461.9M, representing a net margin of 66.0%. Gross margin stands at 83.1%, with free cash flow of -$95.6M. These figures are based on the Q1 2026 filing.
Who are TG Therapeutics's competitors?: TG Therapeutics's key competitors include Biogen Inc., Vor Biopharma Inc. Common Stock, Soligenix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does TG Therapeutics partner with?: TG Therapeutics's notable partners include Neuraxpharm Pharmaceuticals, S.L., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, and others.
What subsidiaries does TG Therapeutics have?: TG Therapeutics's subsidiaries include TG Cell Therapy, Inc..
Where is TG Therapeutics headquartered?: TG Therapeutics is headquartered in United States of America and employs approximately 264 people. It has been publicly traded since 1995.